by Travis DeGraff
As you may recall the last great stimulant of our time has been facing a lot of FDA pressure in recent years. 1,3-dimethylamylamine (DMAA), or geranium extract is a rare find in most products. In 2012 and 2013 there was a litany of debate as to whether DMAA was truly safe. The FDA’s assessment, despite the research, was that it was not and the adverse event reports were alarming. In order to be a dietary supplement, you must be able to show that it is reasonably safe according to DSHEA guidance (the over ruling “law” regarding supplements).
Since that time the majority of supplement companies have re-formulated their preworkout and fat burners to remove DMAA. The few that have continued selling it are very small companies that tend to fly under the radar in hopes the FDA will not notice. This week two companies were asked to “voluntarily” recall their DMAA containing products.
Beta Labs which operates out of Memphis, Tennessee has recalled Oxyphen XR a 12 hour fat burner, Phentalene an ephedra extract fat burner, PHEnFX, and Red Vipers. Ironically one study published in the same city out of Memphis University found that DMAA and caffeine were safe [REF 1].
Beta Labs, unlike some other companies who label DMAA as pelargonium graveolens extract, actually listed DMAA as methylhexamine hcl. Methylhexamine hcl is just another name for DMAA, so they were’nt exactly being shy about selling the stuff. In others such as Phentalene they just listed it as 1,3-dimethylamylamine DMAA. Needless to say, it caught the attention of the FDA.
Regeneca – RegeneSlim Appetite Control
What’s better than a multi-level marketing supplement company!? Perhaps one that also has unlabeled DMAA in their products. Which is exactly what the FDA found in Irvine, CA based Regeneca’s RegeneSlim appetite control product. So unlike Beta Labs, these guys were at least trying to hide it. That or they simply had poor quality control procedures and manufacturing.
It’s safe to say at this point that the few small companies still selling DMAA are doing so under a limited window of opportunity.